FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome
The U.S. Food and Drug Administration granted accelerated approval to tividenofusp alfa, sold as Avlayah, as the first enzyme‑replacement therapy that crosses the blood‑brain barrier for neurologic Hunter syndrome. The drug combines iduronate‑2‑sulfatase with a transport protein to reach both peripheral tissues and the central nervous system. Phase 1/2 data showed a 91% reduction in cerebrospinal fluid heparan sulfate and early improvements in cognitive and adaptive measures. Continued approval will depend on outcomes from the phase 2/3 COMPASS trial.
Connected Medical Devices: Smarter Care Starts Here
Connected medical devices (CMD) are becoming essential for gathering real‑world patient data and supporting decentralized clinical trials. Their integration—from wearable biosensors to continuous glucose monitors—requires dedicated service lines that manage calibration, storage, and data flow. Companies such as Marken are...
Predictive Analytics in Pharma Turns Lab Data Into Launch Strategies
Pharmaceutical firms pour over $300 billion into R&D each year, yet only about 12% of clinical‑trial candidates secure FDA approval. As therapies become more precise, identifying eligible patients and the physicians who treat them grows increasingly complex. Quest Diagnostics highlights that...
Rethinking Dermatology Trial Design for Late-Stage Success
Advances in immunology have spurred many new dermatology therapies, but late‑stage trial failures often stem from outdated trial designs. Traditional short‑term efficacy endpoints like PASI or EASI miss critical data on durability, patient‑reported outcomes, and long‑term safety. Experts advocate incorporating...
Eco-Friendly Synthesis and Characterization of Eggshell-Derived Calcium-Deficiency Bone-Like Hydroxyapatite
The study introduces a two‑step thermal method that leverages the intrinsic pH 10 of calcined eggshell powder to synthesize phase‑pure calcium‑deficiency hydroxyapatite (CDHA) without added NaOH, KOH, or phosphoric acid. First, eggshells are calcined at 900 °C to form CaO; then the...
Regeneron and Sanofi Report the EC Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)
Regeneron and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for moderate‑to‑severe chronic spontaneous urticaria in children aged 2‑11 who remain symptomatic despite antihistamines. The decision follows two Phase‑III studies—LIBERTY‑CUPID and CUPIDKids—that demonstrated significant reductions in UAS7 scores...
MGI Tech Celebrates 10 Years of Innovation, Empowering 3,560 Users Across Six Continents
MGI Tech marks its 10th anniversary, now supporting 3,560 users and 5,300 installations across six continents. The company’s flagship T20×2 platform has driven whole‑genome sequencing costs below $100 per genome, while newer T1+ and T7+ systems deliver terabyte‑scale data in...
Boehringer Ingelheim Introduces LENZELTA®: A New Vaccine Advancing Mastitis Prevention in Dairy Cows
Boehringer Ingelheim has launched LENZELTA®, a new mastitis vaccine for dairy cows that requires two doses during the dry‑off period. The oil‑free formulation targets Staphylococcus aureus and Escherichia coli, delivering the earliest onset of immunity and protection lasting up to...
Miracell Reports US FDA 510(k) Clearance for SMART M-CELL PRP and Bone Marrow Concentration Systems
Miracell announced that the U.S. Food and Drug Administration granted 510(k) clearance for its SMART M-CELL PRP Concentration System and Bone Marrow Concentration System, including the related kits. The clearance was based on substantial equivalence to the previously cleared SmartPReP...
A Pioneer Compilation on Ibrutinib-Loaded Hybrid Nanoformulations for Different Types of Cancer
Researchers Pandey, Gautam, and Singh review hybrid nanoformulations that encapsulate ibrutinib, a BTK inhibitor used for chronic lymphocytic leukemia and mantle‑cell lymphoma. The paper details how polymeric nanoparticles, liposomes, dendrimers and SNEDDS improve ibrutinib’s solubility, bioavailability, and pharmacokinetics while reducing...
Profile of Helen M. Piwnica-Worms
Helen M. Piwnica‑Worms, a veteran cancer biologist, has spent decades dissecting how tumor cells bypass cell‑cycle checkpoints and develop drug resistance. Her early work clarified the role of tyrosine phosphorylation in src and cdc2 regulation, laying groundwork for modern checkpoint...
EU Asked to Include Microbial Proteins & Fermentation in Upcoming Biotech Act
Climate advocacy group WePlanet is urging the European Union to explicitly include advanced fermentation—single‑cell proteins, mycelium and precision‑fermentation products—in the upcoming Biotech Act II, slated for Q3 2026. The brief argues that Europe’s food system is overly dependent on imported soy and...
Repairing Aging Blood‑Brain Barrier to Halt CNS Disease
Aging of the Blood-Brain Barrier and Altered Permeability to Peripheral Immune Cells: Implications for Central Nervous System Disorders "We discuss interventions focused on barrier repair and immune recalibration, including the reinforcement of tight junctions, restoration of pericyte homeostasis, and modulation of...
#387 – AMA #83: Peptides—Evaluating the Science, Safety, and Hype in a Rapidly Growing Field
Peter’s AMA on gray‑market peptides demystifies a fast‑growing, often misunderstood segment of the wellness industry. He introduces a four‑point framework—mechanism, evidence, safety, and regulatory status—to assess any peptide claim. The episode walks through real‑world case studies such as SS‑31, melanotan‑II,...
FDA’s CRL Transparency Policy Is Boosting Biopharma Accountability
More than a year after the FDA launched its radical transparency agenda, the agency has released over 200 complete response letters (CRLs) covering 2020‑2024 and added historic letters back to 2002. Public availability forces biotech firms to align their disclosures...
Weight-Loss Drugs and Mars Bars: Novo Nordisk’s Comeback Bid
Novo Nordisk is launching a next‑generation obesity drug to revive growth after a slowdown in its diabetes franchise. The company projects $5 billion in sales from the new semaglutide‑based therapy by 2028, targeting a global obesity market estimated at $250 billion. To...
Your Scale, Your Terms: How Modular Bioreactors Are Redefining Capacity & Manufacturing Strategies
AGC Biologics is championing a scale‑out strategy that uses modular single‑use bioreactors instead of traditional stainless‑steel scale‑up. Its proprietary 6Pack System™ links up to six 2,000‑liter disposable reactors, delivering flexible capacities from 2 kL to 12 kL while preserving process parameters. The approach...
Weizmannia Coagulans BC99 Presents Promising Probiotic Strategy for Chronic Constipation
A double‑blind, placebo‑controlled trial of 88 adults showed that daily intake of Weizmannia coagulans BC99 (10 billion CFU) for eight weeks markedly improved bowel‑movement frequency, stool form and psychological well‑being. Participants receiving BC99 experienced faster colonic transit, higher levels of motility‑promoting peptides and...
Aspirin May Fight Cancer — But Not for the Reason You Think
Researchers at Tahoe Therapeutics assembled a 100‑million‑cell dataset to ask whether drugs can push cancer cells back toward a normal gene program. Using this approach, they confirmed known colon‑cancer therapies and discovered that sodium salicylate—aspirin without its acetyl group—reverses cancer‑state...
Stanford Scientists Discover “Natural Ozempic” Without Side Effects
Stanford Medicine scientists have identified a naturally occurring 12‑amino‑acid peptide, dubbed BRP, that mimics the appetite‑suppressing effects of semaglutide (Ozempide) in animal models. In lean mice and minipigs, a single injection cut food intake by up to 50% and daily...
Discrepancy in Mouse Counts Raises Partial Reprogramming Concerns
okay, tell me why you think browder et al had 21 mice in -dox and only 15 mice in the +dox group when they did partial reprogramming? https://t.co/gedJiKSRKo 6 more mice in the dox group got tummy aches and asked out of...
Rapid Lab Automation Needed to Scale Bio Testing
Interesting take on lab automation and serial scale vs parallel scale for data generation. Innovation in how we can rapidly Test more and more in the lab is badly needed as Design, Build and Learn capabilities in bio have exploded...
Amneal Projects $3.1B 2026 Revenue, Leverages Pfizer GLP‑1 Manufacturing Deal
Amneal Pharmaceuticals guided 2026 revenue to $3.05‑$3.10 billion and highlighted a manufacturing partnership with Pfizer’s Metsera unit for GLP‑1 therapies. The plan leans on a diversified portfolio, accelerated affordable‑medicine launches, and a shift toward higher‑value injectables, while specialty sales face flat...
OSK Reprogramming Triggers Tumors, Undermining Mouse Study Confidence
OSK reprogramming also produces tumors see https://t.co/dNhcHVSBf3 cancer is a selective process clones grow out because they have a proliferative advantage or apoptotic disadvantage when mouse papers say no cancer despite the fact that half of lab mice die from cancer, i don't feel...
FDA’s Fiscal Year 2027 Budget Is Chock-Full of Legislative Proposals – Especially on Hatch-Waxman and the BPCIA
The FDA’s FY2027 budget request bundles 27 legislative proposals into its Justification of Estimates for Appropriations Committees, a sharp increase from prior years. Highlights include allowing U.S. generic manufacturers to file Paragraph IV certifications a month earlier, deeming all approved...
Eli Lilly to Acquire Centessa, Adding Orexin‑Based Sleep‑Wake Drugs
Eli Lilly announced in 2026 that it will acquire Centessa Pharmaceuticals, a biotech focused on orexin‑2 receptor agonists for sleep‑wake disorders. The deal includes cash and contingent value rights tied to regulatory milestones, positioning Lilly to accelerate development of cleminorexton,...
Pleiotropic Modulation of the Gut-Brain-Lung Axis by Ketamine and Its Enantiomers
A new review examines how ketamine and its enantiomers reshape the gut‑brain‑lung axis by modulating microbiota, microbial metabolites, and immune‑cell trafficking. Both arketamine (R‑ketamine) and esketamine (S‑ketamine) reduce systemic inflammation, but they differ mechanistically: arketamine leverages vagus‑mediated gut‑brain signaling, while...
Singapore-Listed IX Biopharma Bets Big on Non-Opioid Pain Relief
Singapore-listed IX Biopharma has advanced its sublingual ketamine wafer, Wafermine, through Phase 2 trials and secured a $40.95 million contract from the U.S. Department of Defense to fund Phase 3 development and an Emergency Use Authorization. The FDA has accepted the Phase 2 data,...
Bladder Toxicity Risk Appears Low for Psychiatric Ketamine Patients, Though Data Is Limited
A systematic review of 27 clinical studies found that short‑term ketamine and esketamine treatments for psychiatric disorders do not significantly increase bladder or urinary tract toxicity compared with placebo. Reported urinary symptoms ranged from 0 % to 25 % and were generally...
CDC Caught Burying Report on Real Effects of COVID Vaccine
A CDC report led by acting director Jay Bhattacharya found that COVID‑19 vaccines cut urgent‑care visits by 50% and hospitalizations by 55% for healthy adults. The study, slated for the Morbidity and Mortality Weekly Report on March 19, was delayed over...
Try My Pre‑Alpha TUI Plasmid Editor via Pip
If any1 wants to try my very unpolished and unfinished TUI plasmid editor in its very pre-alpha form, I reserved a slot on the ol pip bandwagon. Just type in: pip install splicecraft and I recommend runnin this often to update: pip install...
WATCH: Former Pfizer Europe Chief Toxicologist Testifies Pfizer Vaccine Should Never Have Been Released, Calls Mass Rollout a “Human Experiment”
In March 2026, a former Pfizer Europe chief toxicologist testified before a German parliamentary committee, alleging that critical safety studies for the Comirnaty COVID‑19 vaccine were skipped. He claimed carcinogenicity tests were omitted, reproductive toxicity data were inadequate, and the...
Loyal's Longevity Pill Shows One‑Year Lifespan Boost in 1,300‑Dog Trial
San Francisco‑based Loyal announced that its experimental drug LOY-002 extended the median lifespan of senior dogs by at least one year in a randomized, double‑blind trial of 1,300 animals. The result fuels hopes for a pet anti‑aging therapy and raises...
Catalyst Pharma $1,000 Investment Soars 2,145% Over 10 Years, Outpacing S&P 500
Investors who bought Catalyst Pharmaceuticals (CPRX) in April 2016 would see a $1,000 investment swell to $22,456 by April 2026, a 2,145% return that eclipses the S&P 500’s 233% gain. The surge reflects strong sales of Firdapse, new FDA approvals,...
Autolus Shows 77% Response Rate for Obe‑cel CAR‑T in New Real‑World and Pediatric Data
Autolus Therapeutics unveiled new real‑world and pediatric data for its CD19‑directed CAR‑T, obe‑cel, reporting a 77% overall response rate in the FELIX trial and 91 infusions in the ROKA consortium with 84 evaluable patients. The findings address a major unmet...
StockWatch: IPO Market Shows Sign of Life with Avalyn Filing
Avalyn Pharma, a Boston‑based biotech, filed an S‑1 on Wednesday seeking up to $100 million to advance its inhaled antifibrotic pipeline for pulmonary fibrosis. The filing marks the first biotech IPO since Generate: Biomedicines raised $400 million and revives a market that...
IPSC Therapies Succeed; In‑vivo Reprogramming Remains Hype
your regular reminder that Yamanaka factor-driven production of iPSCs is already producing real medicine (eg dopaminergic neural progenitor for Parkinson's, cardiomyocyte sheets for heart failure & more) iPSC tech is not done in vivo... ppl isolate the well behaved cells away...
Daily Evoked Gamma Therapy Shows Safety and Cognitive Benefit
Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease 👉 “Our results demonstrate that 1-h daily treatment with [CogTx-001] was safe and well-tolerated and demonstrated potential clinical benefits in mild to moderate AD.” 🔘 Participants underwent...
As RSV Evolves, a Two‑pronged Antibody Cocktail Aims to Stay Ahead
Chinese researchers at Xiamen University have engineered a two‑antibody cocktail, 1A2 and 1B6, that targets separate, conserved regions of the RSV fusion protein. Preclinical tests in mice and cotton rats showed the combo neutralized both RSV A and B subtypes...
AbbVie’s Mirvetuximab Shows
AbbVie combo mirvetuximab posts 62.7% ORR; median DOR 11.2m. Efficacy boosts pipeline vs rich valuation and R&D hit. Trading insight: buy on pullback ahead of catalysts. 📈 — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov
AI Powers Cancer Cures While Robots Learn Chores
AI is designing molecules that boost chemotherapy effectiveness by 70%, and humanoid robots are learning tasks by watching gig workers record themselves doing chores... we're literally teaching machines to cure cancer AND do our laundry.
Two New Takes on Making a Type of Targeted Cancer Therapy Even Better
Two biotech startups announced fresh capital to boost next‑generation antibody‑drug conjugates (ADCs). Sidewinder Therapeutics raised a $137 million Series B, bringing total funding to $162 million, to develop bispecific ADCs that bind a tumor‑driving receptor and an internalizing receptor, aiming for tighter cancer...
Targeted mRNA Nanoparticles Halt Lung Tumors and Cachexia
Follistatin mRNA delivered via targeted lipid nanoparticles enables a dual therapeutic effect by simultaneously suppressing lung tumor growth and preventing cancer-associated muscle wasting (cachexia). https://t.co/56fCFZU0vk
Aging Opens Chromatin, Altering Cell Behavior
The researchers then looked into the changes in the old cells that might explain such pronounced differences in behavior compared with the young cells. Liao Says "It seems as though chromatin opens up with age, so to speak." https://t.co/1kdRDunTea
Immune Cells in the Nose Slow Influenza Virus, Study Finds
A University of Gothenburg study reveals that CD4 memory T cells linger in the nasal lining and can quickly reactivate when influenza re‑enters the body, curbing viral replication. In mouse models these resident cells lowered viral loads and limited tissue...
24/7 Green Lab Services Available for $49‑$150
Great list of services from @americanwetware to ultimately have available 24/7. We have most of the green ones already in place w/ protocols in Ginkgo Cloud Lab for $49-$150, still need to add solubility measurement but can do that...
Targeted Microbubble Therapy Cuts Kidney Damage in Rat Model of Chemotherapy‑Induced AKI
Researchers led by Si, Mo and Zhao demonstrated that E‑selectin‑targeted microbubbles combined with ultrasound dramatically improve methylprednisolone’s renoprotective effect in rats with cisplatin‑induced acute kidney injury, cutting serum creatinine and preserving tubular cells. The pre‑clinical breakthrough points to a new...
Re: The Power of the Markets: The Scandal that Keeps on Taking
A letter to the BMJ criticizes the pharmaceutical industry’s reliance on experimental trials that deny patients post‑trial access to new drugs. It argues that powerful, profit‑driven groups manipulate regulations, limiting transparency and compromising the NHS’s ability to provide affordable treatments....
Replimune Faces Likely FDA Denial of RP1 Gene Therapy on April 10
Replimune Group Inc. is poised for an FDA decision on Friday, April 10, that is expected to deny its RP1 gene‑therapy plus nivolumab BLA. The agency says the IGNYTE trial does not meet standards for a well‑controlled study, a blow...
The Psychedelic Revolution
The episode explores the emerging field of psychedelic therapy, highlighting its potential to treat treatment‑resistant mental health conditions with a few supervised dosing sessions rather than daily medication. Guests Dr. Will Vanderveer and Keith Kurlander explain how the approach combines...